Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362815 | 1.00 | MAPT (0.53) | MAPTMAPK1TDP1ABCB1ALDH1A1 | |
| SCHEMBL25893256 | 1.00 | MAPT (0.53) | MAPTMAPK1TDP1ABCB1ALDH1A1 | |
| SCHEMBL24103715 | 1.00 | MAPT (0.53) | MAPTMAPK1TDP1ABCB1ALDH1A1 | |
| SCHEMBL19787655 | 0.93 | ESR1 (0.53) | MAPTMAPK1TDP1ABCB1ALDH1A1 | |
| SCHEMBL25892444 | 0.90 | MAOB (0.45) | MAPTMAPK1TDP1ABCB1ALDH1A1 | |
| SCHEMBL25892495 | 0.90 | MAOB (0.45) | MAPTMAPK1TDP1ABCB1ALDH1A1 | |
| SCHEMBL2604725 | 0.90 | MAOB (0.45) | MAPTMAPK1TDP1ABCB1ALDH1A1 | |
| SCHEMBL20831829 | 0.88 | ESR1 (0.58) | MAPTMAPK1TDP1ALDH1A1ESR1 | |
| SCHEMBL20831831 | 0.88 | ESR1 (0.58) | MAPTMAPK1TDP1ALDH1A1ESR1 | |
| SCHEMBL15312307 | 0.88 | ESR1 (0.58) | MAPTMAPK1TDP1ALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436680-B1 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2016-05-18 | — | — | EP | claimed |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-07-05 | — | — | US | claimed |
| EP-1809618-A4 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RES PTY LTD (AU) | 2008-11-19 | — | — | EP | claimed |
| EP-1809618-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | Novogen Research Pty Ltd (AU) | 2007-07-25 | — | — | EP | claimed |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | claimed |
| WO-2006032086-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | WO | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| CN-116139125-A | Combination therapy | 梅制药公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116113414-A | Combination therapy | 梅制药公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-4164632-A1 | COMBINATION THERAPIES | MEI Pharma, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2010022467-A1 | IMMUNOMODULATING ACTIVITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2010-03-04 | — | — | WO | disclosed |
| EP-2120925-A1 | METHOD FOR INDUCING AUTOPHAGY | Novogen Research Pty. Ltd. (AU) | 2009-11-25 | — | — | EP | disclosed |
| EP-1809618-A4 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RES PTY LTD (AU) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008113100-A1 | METHOD FOR INDUCING AUTOPHAGY | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-25 | — | — | WO | disclosed |
| EP-1809618-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | Novogen Research Pty Ltd (AU) | 2007-07-25 | — | — | EP | disclosed |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
| WO-2006032086-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | MAPT 3327/4885MAPK1 938/4885TDP1 1949/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | MAPT 2864/4885MAPK1 3494/4885TDP1 1161/4885 |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAPT 2679/4885MAPK1 2444/4885TDP1 460/4885 |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | CDYL, XPA, TP53 | MAPT 2679/4885MAPK1 2444/4885TDP1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.